You are here

Merck

One of Merck’s pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

Endpoints

Thu, 12/14/17 - 09:25 pm

clinical trials

Merck says it has restored most of its manufacturing hit by cyberattack

Fierce Pharma

Wed, 12/13/17 - 11:25 am

Why 2017 Was a Year to Forget for Merck & Co. Inc.

Motley Fool

Thu, 12/7/17 - 09:35 am

J&J, Lilly, Merck have best management in pharma, says report

BioPharma Dive

Wed, 12/6/17 - 11:54 pm

Wall Street Journal

In Supreme Court petition, Merck argues that FDA power shields against liability

Fierce Pharma

Wed, 12/6/17 - 11:46 pm

Republican tax bill makes big winners of Amgen, Gilead and other drugmakers

Marketwatch

Wed, 12/6/17 - 09:48 am

Gilead Sciences

offshore accounts

Executive of the Year: Kenneth Frazier

BioPharma Dive

Tue, 12/5/17 - 09:32 am

Kenneth Frazier

Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: study

Fierce Pharma

Mon, 12/4/17 - 11:45 am

Recent Developments for Merck’s Keytruda

Market Realist

Fri, 12/1/17 - 12:02 pm

immuno-oncology

anti-PD-1 immunotherapy

non-small cell lung cancer

Gloomy results from the research for an Alzheimer’s therapy

GoinPharma

Thu, 11/30/17 - 09:54 am

Alzheimer's disease

Denali Therapeutics

Yumanity Therapeutics

drug development

Merck blueprints $1.3B research hub in a post-Brexit London, with 950 staffers

Endpoints

Mon, 11/27/17 - 09:08 am

drug development

3 Companies Competing to Gain Lead in Ovarian Cancer Market

Yahoo/Zacks.com

Sat, 11/25/17 - 12:35 pm

Clovis Oncology

Merck will delay filing Ebola vaccine for approval until 2018, company confirms

Fierce Pharma

Sat, 11/25/17 - 12:30 pm

HPV Vaccination Immunity Remains Strong 10 Years Later, Especially For Preteens

Forbes

Fri, 11/24/17 - 09:27 am

Startup seeking to resurrect Vioxx, arthritis drug pulled from market

Stat

Tue, 11/21/17 - 09:53 am

Tremeau Pharmaceuticals

Merck strikes autoimmune deal with newly-emerged Cue

BioPharma Dive

Fri, 11/17/17 - 10:18 am

autoimmune disease

drug development

How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas

Fierce Pharma

Thu, 11/16/17 - 11:27 am

Bristol-Myers Squibb

Gilead Sciences

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

Fierce Pharma

Wed, 11/15/17 - 08:51 pm

Clovis Oncology

PARP inhibitors

Merck, GlaxoSmithKline face hepatitis A vaccine shortage amid U.S. outbreaks

Fierce Pharma

Wed, 11/15/17 - 08:46 am

Heron takes on Merck's Emend with FDA win for antinausea drug Cinvanti

Fierce Pharma

Fri, 11/10/17 - 09:39 am

Heron Therapeutics

chemotherapy-induced nausea and vomiting

Pages